II. Epidemiology: SGLT2 Inhibitor Associated Ketosis

  1. Initially 73 reported cases in 2 years for patients on SGLT2 Inhibitors with Serum Glucose <250 mg/dl
  2. Subsequently 2500 cases with patients on SGLT2 Inhibitors reported to FDA
    1. Fadini (2017) Diebetologia 60(8): 1385-9 [PubMed]

III. Mechanism: SGLT2 Inhibitor Associated Ketosis

  1. Sodium-Glucose Co-Transporter-2 Inhibitor (SGLT2 Inhibitor) are Oral Hypoglycemic agents in Type II Diabetes
  2. SGLT2 Inhibitors block Glucose reabsorption in the Kidneys, with Glucose excreted in the urine
  3. Results in lower Blood Sugars, results in decreased Insulin release
  4. May result in increased Fatty Acid breakdown and Ketone production due to Hypoglycemia
    1. SGLT2 Inhibitor may also directly increase Fatty Acid breakdown and Ketone production

IV. Risk Factors: SGLT2 Inhibitor Associated Ketosis

  1. Increased risk with renal Impairment (as well as dehydration, acute illness)
    1. Avoid Farxiga (Dapagliflozin) if GFR <60 ml/min
    2. Avoid Invokana (Canagliflozin) and Jardiance (Empagliflozin) if GFR <45 ml/min

V. Symptoms

  1. Onset as early as first 2 weeks of starting an SGLT2 Inhibitors
  2. Nausea and Vomiting
  3. Fatigue

VI. Signs

  1. Dehydration
  2. Tachypnea
  3. Sinus Tachycardia
  4. Confusion

VII. Labs

IX. Management: SGLT2 Inhibitor Associated Ketosis

  1. Similar management as with Diabetic Ketoacidosis Management
  2. Initiate fluid bolus
  3. Start D10 infusion
  4. Start Insulin 0.1 units/kg/h infusion (do not give Insulin bolus)
    1. Confirm normal Potassium before initiating Insulin

XI. References

  1. Swaminathan and Hayes in Herbert (2019) EM:Rap 19(6): 12

Images: Related links to external sites (from Bing)

Related Studies (from Trip Database) Open in New Window